Genomics

Khosla Ventures

Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.

Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.

Khosla Ventures

Check: In a 2020 first-person interview, Samir described a typical Khosla Seed Fund investment as roughly $1M–$2M, used as option-value capital to remove key risks before a larger Series A/B decision. Khosla's current Main Fund covers early through later stages, including total financings above $10M. These are historical/firm-level guideposts, not a guaranteed current personal range.

Samir prefers large, known markets where a radical technical risk can produce a 10x-better product. He treats small seed checks as option-value experiments: identify a potential billion-dollar outcome, use capital to remove a binary technical, team, or market-development risk, then redo the diligence and concentrate capital if the evidence improves. He rejects mechanical pro-rata, values non-consensus decisions, and believes uncapped upside justifies bold technical bets rather than conservative hit-rate optimization.